Pine Labs Ltd. has launched its initial public offering with a price band of Rs 210–Rs 221 per share. Should you invest? Read our in-depth analysis for key details and expert insights.
Vodafone Idea is set to declare its Q2FY26 results next week. Check the date, earnings call schedule, and share price history to make informed investment decisions.
Piramal Finance has relisted on the stock exchanges at a 12% premium. Find out what this means for Indian investors and the broader implications for the NBFC sector.
Get the latest updates on MAS Financial Services’ Q2 performance, Axis Securities’ ‘Buy’ recommendation, and the outlook for the NBFC sector in India.
Astral Ltd.’s Q2 FY26 results were above estimates, but IDBI Capital downgraded the stock to ‘Hold’ due to limited upside potential. What does this mean for investors?
Get the latest updates on Updater Services’ Q2 results, Motilal Oswal’s downgrade, and its implications for Indian investors.
ICICI Securities has maintained its ‘Hold’ rating on Zydus Lifesciences Ltd. with a lower target price of Rs 900, citing a 4% downside. The company’s Q2 FY26 revenue was driven by recent acquisitions in consumer wellness and medtech divisions, but subdued margins and lower revenue of gRevlimid impacted Ebitda margin.
Mark Matthews, Head of Research Asia at Julius Baer, discusses the differences between the Indian and Chinese markets, and how both can continue to grow in parallel.
Indigo Paints Ltd.’s Q2 FY26 results have been reviewed by ICICI Securities, which has cut the target price despite maintaining an ‘Add’ rating. Find out why.
Lenskart, set to list on Monday, receives its first sell rating from Ambit due to valuation concerns and a capital-intensive business model.